PDF Cover

Pretomanid Market

The market for Pretomanid was estimated at $459 million in 2024; it is anticipated to increase to $712 million by 2030, with projections indicating growth to around $1.03 billion by 2035.

Report ID:DS1802142
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Pretomanid
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Pretomanid Market Outlook

Revenue, 2024

$459M

Forecast, 2034

$955M

CAGR, 2025 - 2034

7.6%

The Pretomanid industry revenue is expected to be around $494.0 million in 2025 and expected to showcase growth with 7.6% CAGR between 2025 and 2034. Building on this growth trajectory, the Pretomanid market is gaining strategic importance within the global tuberculosis treatment landscape, particularly in addressing multidrug-resistant and extensively drug-resistant (XDR) TB cases. Its increasing adoption is primarily driven by rising global TB burden, stronger public-private partnerships, and ongoing support from international health organizations. Favorable regulatory pathways, coupled with inclusion in combination regimens recommended by global health bodies, are accelerating its penetration in high-burden regions. Additionally, expanding access programs, improved diagnostic capabilities, and government-led eradication initiatives are reinforcing demand. Market participants are also focusing on strengthening supply chains and enhancing affordability, ensuring broader patient reach. As healthcare systems prioritize effective and shorter-duration therapies, Pretomanid continues to gain recognition as a critical component in modern TB treatment protocols.

Pretomanid is a novel nitroimidazooxazine antimicrobial agent specifically developed for use in combination therapies to treat drug-resistant forms of tuberculosis. It functions by inhibiting mycolic acid synthesis and releasing reactive nitrogen species, thereby effectively targeting persistent bacterial populations. Primarily used in regimens such as BPaL (bedaquiline, pretomanid, and linezolid), it has demonstrated high efficacy and reduced treatment duration compared to conventional therapies. Key applications are concentrated in pulmonary MDR-TB and XDR-TB treatment, particularly in low- and middle-income countries with high disease prevalence. Recent trends driving demand include increased adoption of all-oral treatment regimens, growing clinical evidence supporting safety and effectiveness, and expanded approvals across multiple regions. Furthermore, ongoing research into optimized combination therapies and broader accessibility initiatives is expected to enhance its clinical adoption and market expansion.

Pretomanid market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Pretomanid Market Outlook

Market Key Insights

  • The Pretomanid market is projected to grow from $459.1 million in 2024 to $955 million in 2034. This represents a CAGR of 7.6%, reflecting rising demand across Tuberculosis Treatment, Preclinical Cancer Research, and Antimicrobial Resistance Counteraction.

  • TB Alliance, Mylan NV, and Sequire Life Sciences are among the leading players in this market, shaping its competitive landscape.

  • U.S. and UK are the top markets within the Pretomanid market and are expected to observe the growth CAGR of 4.9% to 7.3% between 2024 and 2030.

  • Emerging markets including India, South Africa and Brazil are expected to observe highest growth with CAGR ranging between 8.7% to 10.5%.

  • Transition like Shift from Injectable Regimens to All-Oral Drug-Resistant Tuberculosis Therapies is expected to add $67 million to the Pretomanid market growth by 2030.

  • The Pretomanid market is set to add $496 million between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    rise in multidrug-resistant tuberculosis, and

    Increased Access to Tuberculosis Diagnostics, Pretomanid market to expand 108% between 2024 and 2034.

pretomanid market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Pretomanid - Country Share Analysis

Opportunities in the Pretomanid

India presents a significant growth opportunity for pretomanid due to its high burden of multidrug-resistant tuberculosis and strong government commitment toward TB elimination. National programs are increasingly adopting shorter, all-oral regimens, creating demand for pretomanid-based therapies, particularly in public healthcare systems. Strategic collaborations with global health organizations and local manufacturers are improving drug accessibility and affordability. The oral tablet form used in BPaL and BPaLM regimens is also expected to witness the highest uptake, especially in government-funded treatment centers, where large patient volumes and policy support drive rapid adoption.

Growth Opportunities in North America and Asia Pacific

In North America, particularly in the United States, the pretomanid market is characterized by advanced healthcare infrastructure, strong regulatory support, and a focus on innovation in antimicrobial therapies. Key drivers include increasing investment in antimicrobial resistance programs, government funding for TB research, and the presence of leading pharmaceutical companies. Opportunities are centered around clinical research expansion, development of next-generation combination therapies, and potential label expansions into broader patient populations. Competition is moderate, with a limited number of players engaged in drug-resistant TB treatment, but high entry barriers due to stringent regulatory requirements. Additionally, collaborations between research institutions and pharmaceutical companies are enhancing innovation pipelines. While the overall TB burden is lower compared to developing regions, the focus on high-value therapies and innovation sustains steady market growth.
The Asia Pacific pretomanid market is driven by the high burden of drug-resistant tuberculosis, particularly in countries such as India and China, where national TB elimination programs are accelerating adoption of advanced treatment regimens. Strong government initiatives, support from global health organizations, and increasing integration of all-oral therapies are key growth drivers. Top opportunities lie in expanding access through public healthcare systems, scaling local manufacturing, and increasing adoption of BPaL and BPaLM regimens. Competitive dynamics are shaped by partnerships between TB Alliance and generic manufacturers, which enhance affordability and supply. However, competition remains limited due to the specialized nature of drug-resistant TB therapies. Overall, rising awareness, improved diagnostics, and policy-driven demand continue to strengthen market penetration across emerging economies in the region.

Market Dynamics and Supply Chain

01

Driver: Rising global burden of drug-resistant tuberculosis and expanding combination therapy adoption

The increasing incidence of multidrug-resistant and extensively drug-resistant tuberculosis is also a primary factor driving demand for pretomanid. Health systems across high-burden regions are also facing challenges with prolonged, less effective legacy treatments, creating a strong need for newer therapeutic options. Pretomanid addresses this gap through its inclusion in shorter, more effective all-oral regimens, significantly improving treatment outcomes and patient compliance. Alongside this, the growing adoption of combination therapies such as BPaL and BPaLM reflects a broader industry shift toward multi-drug strategies designed to minimize resistance and enhance efficacy. Clinical validation of these regimens, supported by global health organizations, is also accelerating their integration into national TB programs. This dual momentum of rising disease burden and increasing reliance on optimized combination therapies is also strengthening pretomanid’s role as a cornerstone drug in modern tuberculosis management frameworks.
A key driver for the pretomanid market is also the increasing emphasis on expanding access to advanced TB treatments through global health initiatives and supportive regulatory frameworks. International organizations and non-profit alliances are also actively facilitating licensing agreements and technology transfers to ensure affordability and availability in low- and middle-income countries. This is also complemented by accelerated approval pathways and inclusion in essential medicine guidelines, which streamline market entry and adoption. The growing focus on equitable healthcare access is also also encouraging public–private partnerships that enhance distribution networks and local manufacturing capabilities. These developments are also not only improving patient reach but also fostering innovation in treatment delivery models. As a result, pretomanid is also benefiting from a favorable ecosystem that promotes both accessibility and sustained market penetration.
02

Restraint: Significant safety concerns and adverse drug reactions limiting widespread clinical adoption

Pretomanid-based regimens are associated with notable safety concerns that restrict broader clinical acceptance, particularly in resource-constrained healthcare settings. Documented adverse effects such as hepatotoxicity, bone marrow suppression, peripheral neuropathy, and cardiac rhythm abnormalities necessitate continuous patient monitoring and specialist oversight. These safety risks increase treatment complexity and cost, discouraging smaller healthcare providers from adopting the drug widely. For example, mandatory liver function tests and management of side effects can strain hospital resources, reducing prescription rates. Additionally, concerns over limited long-term safety data further influence cautious physician behavior, ultimately slowing market penetration and impacting revenue growth, especially in decentralized care environments.
03

Opportunity: Integration of pretomanid into advanced combination regimens in hospital settings and Rising investment in antimicrobial resistance programs across global health organizations

The growing shift toward optimized combination therapies in tertiary care hospitals is creating new opportunities for pretomanid. Hospitals are increasingly adopting advanced regimens to improve treatment outcomes for drug-resistant TB cases, particularly in urban healthcare systems with better diagnostic infrastructure. Pretomanid’s role in combination therapies with bedaquiline and linezolid enhances its demand in specialized pulmonary care units. The hospital segment is expected to drive growth, as clinicians prioritize shorter-duration, high-efficacy treatments. This trend is further supported by ongoing clinical research and real-world evidence validating improved patient outcomes with such regimens.
Increasing global focus on combating antimicrobial resistance is opening new avenues for pretomanid adoption. International funding bodies and non-profit organizations are prioritizing innovative anti-infective solutions, especially for resistant tuberculosis strains. Pretomanid benefits from this trend due to its novel mechanism and proven effectiveness in resistant cases. Growth is expected in low- and middle-income regions where donor-funded programs and access initiatives are expanding treatment coverage. The drug’s application in resistance-focused TB programs is likely to grow the fastest, supported by policy frameworks, funding support, and increased awareness of antimicrobial stewardship practices.
04

Challenge: Patent restrictions and limited awareness in developing markets reducing treatment accessibility

Intellectual property challenges and low awareness levels in high-burden regions significantly constrain pretomanid market expansion. Patent extension attempts and exclusivity rights can limit generic competition, leading to higher treatment costs and restricted availability in low- and middle-income countries. This directly affects procurement decisions by governments and global health agencies, reducing overall treatment volumes. Simultaneously, limited awareness among healthcare professionals about pretomanid’s clinical benefits results in underutilization, particularly in developing markets. For instance, lack of training and knowledge dissemination delays inclusion in standard treatment protocols, weakening demand generation. Together, these factors create uneven market access, suppress adoption rates, and constrain the drug’s full commercial potential.

Supply Chain Landscape

1

Raw Material Suppliers

Johnson MattheyBASF
2

Intermediate Product Producers

Mylan LaboratoriesLupin Pharmaceuticals
3

API Manufacturers

PfizerSanofi
4

End-Use

Hospital PharmaciesRetail Pharmacies
Pretomanid - Supply Chain

Use Cases of Pretomanid in Tuberculosis Treatment & Preclinical Cancer Research

Tuberculosis Treatment : Pretomanid is predominantly used as an oral antimicrobial agent within combination regimens for treating drug-resistant tuberculosis, particularly multidrug-resistant and extensively drug-resistant forms. It is most commonly administered as part of standardized therapies such as BPaL, targeting pulmonary TB in adult patients across hospital settings and national TB programs. Its mechanism, involving inhibition of mycolic acid synthesis and release of reactive nitrogen species, enables effective action against both active and dormant bacterial populations. The key advantage lies in its ability to shorten treatment duration and reduce reliance on injectable drugs, improving patient adherence. This makes pretomanid highly valuable for public health systems, especially in high-burden regions with limited healthcare infrastructure.
Preclinical Cancer Research : In preclinical cancer research, Pretomanid is primarily utilized as a hypoxia-activated prodrug in experimental oncology studies. Research institutions and pharmaceutical R&D centers explore its potential due to its selective activation under low-oxygen conditions, which are characteristic of solid tumor microenvironments. This property allows pretomanid to target hypoxic tumor cells that are often resistant to conventional therapies. Its nitroimidazole structure facilitates the generation of reactive intermediates that may induce cytotoxic effects in cancer cells. Although not yet approved for oncology applications, its unique biochemical profile offers a promising pathway for developing targeted cancer therapies, particularly in studies focusing on tumor hypoxia and resistance mechanisms.
Antimicrobial Resistance Counteraction : Pretomanid plays a strategic role in addressing antimicrobial resistance by offering a novel mechanism of action distinct from traditional antibiotics. It is mainly applied in combination therapies to combat resistant bacterial strains, especially Mycobacterium tuberculosis. Healthcare providers and global health organizations deploy pretomanid-based regimens to overcome resistance challenges that limit the effectiveness of existing treatments. Its dual mode of action reduces the likelihood of resistance development and enhances bactericidal activity. The drug’s integration into antimicrobial stewardship programs and global TB elimination initiatives underscores its importance. By improving treatment outcomes and limiting the spread of resistant infections, pretomanid contributes significantly to modern anti-infective strategies.

Recent Developments

Recent developments in the pretomanid market highlight strong momentum in drug-resistant tuberculosis treatment, driven by innovation in combination therapy and access expansion. Notably, pediatric clinical data in 2025 demonstrated safe and effective dosing, supporting broader patient adoption and new formulation development. Simultaneously, pricing strategies such as multi-manufacturer collaborations have reduced treatment costs, improving affordability in high-burden regions. A key trend is the advancement of shorter, all-oral TB regimens like BPaL, reinforcing pretomanid’s role in antimicrobial resistance management and accelerating global market penetration.

March 2026 : TB Alliance announced new leadership expansion and continued strategic focus on scaling access to pretomanid-based regimens through global stakeholder engagement and TB program integration.
November 2025 : TB Alliance reported positive interim pediatric clinical trial data for pretomanid, supporting development of child-friendly formulations and expanding its application into pediatric drug-resistant TB treatment.

Impact of Industry Transitions on the Pretomanid Market

As a core segment of the Pharmaceutical industry, the Pretomanid market develops in line with broader industry shifts. Over recent years, transitions such as Shift from Injectable Regimens to All-Oral Drug-Resistant Tuberculosis Therapies and Transition toward Global Access Partnerships and Decentralized Treatment Distribution Models have redefined priorities across the Pharmaceutical sector, influencing how the Pretomanid market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift from Injectable Regimens to All-Oral Drug-Resistant Tuberculosis Therapies

The Pretomanid market is undergoing a significant transition from traditional injectable-based TB treatments to fully oral regimens, driven by improved patient compliance and evolving clinical guidelines. This shift is accelerating demand for Pretomanid as a core component in shorter-duration therapies such as BPaL. The transition is also influencing adjacent industries, including hospital care delivery and pharmaceutical manufacturing, where reduced reliance on injectables lowers infrastructure and logistics costs. For example, healthcare providers are reallocating resources toward outpatient care models, while drug manufacturers are scaling up oral solid dosage production, reshaping supply chain priorities and improving treatment accessibility.
02

Transition toward Global Access Partnerships and Decentralized Treatment Distribution Models

Another key transition is the movement toward collaborative access models involving global health organizations, governments, and generic pharmaceutical manufacturers. Pretomanid is increasingly distributed through licensing agreements and donor-funded programs, enabling wider reach in low- and middle-income countries. This shift is transforming procurement and distribution practices across the public health and pharmaceutical sectors. For instance, international procurement agencies are prioritizing volume-based purchasing agreements, while local manufacturers expand production under licensing frameworks. This transition enhances affordability and availability, while also creating new competitive dynamics among suppliers and strengthening the role of public health ecosystems in market expansion.